By using structure based virtual screening, we developed a specific SIRT7 inhibitor 2800Z, which enhanced the chemosensitivity of sorafenib and reduced the tumor burden [16], indicating that a combination of sorafenib and 2800Z could serve as new therapeutic option in the treatment of human liver cancer. This evidence concerns the gene SIRT7 and liver cancer.